Literature DB >> 12057168

Radiation-induced sarcoma.

S R Patel1.   

Abstract

Radiation-induced sarcomas can originate in either the irradiated bone or soft tissues. Most of these tumors are high-grade. The most common histologic subtypes are malignant fibrous histiocytoma (MFH) and osteosarcoma, although other histologies (eg, angiosarcoma, rhabdomyosarcoma) can occur. Tumor size and grade are the two most important prognostic factors for soft tissue sarcomas, including those associated with radiation therapy. The therapy is therefore dictated by the risk of distant metastases. High-grade tumors that are larger than 5 cm should be treated with primary chemotherapy followed by a margin-negative surgical excision of the residual disease. All low-grade tumors and high-grade tumors 5 cm or smaller should be treated with a margin-negative surgical excision, and systemic chemotherapy should be considered when a negative margin is difficult or impossible to accomplish. Radiation-induced sarcomas (either MFH or osteosarcoma) originating in bone should be approached with primary chemotherapy followed by a margin-negative excision similar to de novo bone sarcomas. The dose-intensity of the active agents should be adjusted appropriately for the age, performance status, and prior therapy in a given patient.

Entities:  

Mesh:

Year:  2000        PMID: 12057168     DOI: 10.1007/s11864-000-0037-6

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  10 in total

1.  Postradiation bone sarcoma; report of eleven cases.

Authors:  M CRUZ; B L COLEY; F W STEWART
Journal:  Cancer       Date:  1957 Jan-Feb       Impact factor: 6.860

2.  Sarcoma arising in irradiated bone; report of 11 cases.

Authors:  W G CAHAN; H Q WOODARD
Journal:  Cancer       Date:  1948-05       Impact factor: 6.860

3.  Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas.

Authors:  J F Kuttesch; L H Wexler; R B Marcus; D Fairclough; L Weaver-McClure; M White; L Mao; T F Delaney; C B Pratt; M E Horowitz; L E Kun
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

4.  Radiation-induced sarcoma of bone.

Authors:  M Arlen; N L Higinbotham; A G Huvos; R C Marcove; T Miller; I C Shah
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

Review 5.  Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation.

Authors:  N Jaffe; S R Patel; R S Benjamin
Journal:  Hematol Oncol Clin North Am       Date:  1995-08       Impact factor: 3.722

6.  Outcome of radiation-related osteosarcoma after treatment of childhood and adolescent cancer: a study of 23 cases.

Authors:  M D Tabone; P Terrier; H Pacquement; M Brunat-Mentigny; C Schmitt; A Babin-Boilletot; H H Mahmoud; C Kalifa
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

7.  Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.

Authors:  S R Patel; S Vadhan-Raj; M A Burgess; C Plager; N Papadopolous; J Jenkins; R S Benjamin
Journal:  Am J Clin Oncol       Date:  1998-06       Impact factor: 2.339

Review 8.  Clinical aspects of postirradiation sarcomas.

Authors:  E Robinson; A I Neugut; P Wylie
Journal:  J Natl Cancer Inst       Date:  1988-04-20       Impact factor: 13.506

9.  Mutation of the p53 gene in postradiation sarcoma.

Authors:  H Nakanishi; Y Tomita; A Myoui; H Yoshikawa; K Sakai; Y Kato; T Ochi; K Aozasa
Journal:  Lab Invest       Date:  1998-06       Impact factor: 5.662

10.  Radiation-associated sarcoma of bone and soft tissue.

Authors:  M S Brady; J J Gaynor; M F Brennan
Journal:  Arch Surg       Date:  1992-12
  10 in total
  26 in total

Review 1.  Malignant fibrous histiocytoma: past, present, and future.

Authors:  A E Rosenberg
Journal:  Skeletal Radiol       Date:  2003-09-27       Impact factor: 2.199

Review 2.  The effect of X-rays on bone: a pictorial review.

Authors:  H J Williams; A M Davies
Journal:  Eur Radiol       Date:  2005-10-20       Impact factor: 5.315

Review 3.  Osteosarcoma and acromegaly: a case report and review of the literature.

Authors:  G A B Lima; E M S Gomes; R C Nunes; L Vieira Neto; A P A V Sieiro; E P Brabo; M R Gadelha
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

4.  Sarcomatous transformation of EGFR and TP53 mutation-positive metastatic adenocarcinoma of the lungs, masquerading as a primary pleomorphic sarcoma of the proximal femur.

Authors:  Midori Toda-Ishii; Keisuke Akaike; Aiko Kurisaki-Arakawa; Atsushi Arakawa; Kenta Mukaihara; Yoshiyuki Suehara; Tatsuya Takagi; Kazuo Kaneko; Takashi Yao; Tsuyoshi Saito
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

5.  Primary malignant cystic solitary fibrous tumour of the spleen.

Authors:  Rachel Maria Gomes; Dilip Kothari
Journal:  Indian J Surg Oncol       Date:  2012-09-29

6.  Radiation-induced Extra-osseous Osteosarcoma-A Case Report and Review of Literature.

Authors:  Syam Vikram; Surij Salih; Aswathy Krishnan; M P Nizamudheen; Sajith Babu; Sithara Aravind; N Sangeetha; B Sateesan
Journal:  Indian J Surg Oncol       Date:  2013-08-28

Review 7.  Extremity Soft Tissue Sarcoma: Role of Local Control.

Authors:  Elyse J Brinkmann; Safia K Ahmed; Matthew T Houdek
Journal:  Curr Treat Options Oncol       Date:  2020-02-05

8.  Radiation induced osteogenic sarcoma of the maxilla.

Authors:  Om Prakash; Bipin T Varghese; Anita Mathews; Nileema Nayak; Krishnankutty Ramchandran; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2005-07-21       Impact factor: 2.754

Review 9.  [Soft tissue sarcoma: how can posttreatment alterations be distinguished from recurrences?]

Authors:  I-M Noebauer-Huhmann; T Grieser
Journal:  Radiologe       Date:  2017-11       Impact factor: 0.635

10.  Increased metastasis of malignant fibrous histiocytoma in patients with chronic lymphocytic leukemia and non-hodgkin lymphoma.

Authors:  Agnieszka W Kubica; Peter S Rose; Amy L Weaver; Jerry D Brewer
Journal:  Mayo Clin Proc       Date:  2011-08       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.